Ironwood Pharmaceuticals, Inc. (IRWD) Stake Increased by TIAA CREF Investment Management LLC
TIAA CREF Investment Management LLC lifted its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 2.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 361,859 shares of the biotechnology company’s stock after acquiring an additional 9,604 shares during the quarter. TIAA CREF Investment Management LLC owned about 0.24% of Ironwood Pharmaceuticals worth $6,832,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Teacher Retirement System of Texas bought a new stake in Ironwood Pharmaceuticals during the 2nd quarter valued at approximately $192,000. Jane Street Group LLC bought a new stake in Ironwood Pharmaceuticals during the 1st quarter valued at approximately $194,000. Strs Ohio boosted its stake in Ironwood Pharmaceuticals by 63.1% during the 2nd quarter. Strs Ohio now owns 10,600 shares of the biotechnology company’s stock valued at $200,000 after purchasing an additional 4,100 shares during the period. Karp Capital Management Corp bought a new stake in Ironwood Pharmaceuticals during the 1st quarter valued at approximately $201,000. Finally, Raymond James Financial Services Advisors Inc. boosted its stake in Ironwood Pharmaceuticals by 8.0% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 12,161 shares of the biotechnology company’s stock valued at $207,000 after purchasing an additional 898 shares during the period. Institutional investors own 97.90% of the company’s stock.
Several analysts recently weighed in on IRWD shares. BidaskClub upgraded Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Zacks Investment Research upgraded Ironwood Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 17th. Wells Fargo & Company set a $19.00 target price on Ironwood Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, July 22nd. Wood & Company downgraded Ironwood Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Friday, July 21st. Finally, ValuEngine upgraded Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $18.29.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/13/ironwood-pharmaceuticals-inc-irwd-stake-increased-by-tiaa-cref-investment-management-llc.html.
Ironwood Pharmaceuticals, Inc. (NASDAQ IRWD) opened at 15.62 on Friday. The firm’s market cap is $2.34 billion. The firm has a 50-day moving average price of $15.88 and a 200 day moving average price of $16.88. Ironwood Pharmaceuticals, Inc. has a 12-month low of $12.48 and a 12-month high of $19.94.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05). Ironwood Pharmaceuticals had a negative return on equity of 333.83% and a negative net margin of 52.97%. The firm had revenue of $65.10 million for the quarter, compared to the consensus estimate of $70.00 million. During the same quarter in the prior year, the firm earned ($0.16) EPS. The company’s revenue was up 19.7% on a year-over-year basis. Equities research analysts forecast that Ironwood Pharmaceuticals, Inc. will post ($1.10) EPS for the current year.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Stock Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.